RSS   Newsletter   Contact   Advertise with us

Rigel Pharmaceuticals appoints Brian L. Kotzin to board

Share on Twitter Share on LinkedIn
Staff Writer | San Francisco, Ca., USA | August 28, 2017
Rigel PharmaceuticalsAugust 28, 2017, San Francisco, Ca., USA - Rigel Pharmaceuticals, a clinical-stage biotechnology company, announced that Brian L. Kotzin has been appointed to Rigel's board of directors.
Dr. Kotzin brings to Rigel's board three decades of experience in the areas of immunology and inflammation.

A board-certified rheumatologist and internist, Dr. Kotzin is currently Principal Fellow, Clinical Development at Nektar Therapeutics.

From 2004 to 2015, he was Vice President, Global and Clinical Development and Head, Inflammation Therapeutic Area at Amgen, directing the global development efforts for product candidates in the inflammation area.

Before joining Amgen, Dr. Kotzin was the head of Clinical Immunology in the Department of Medicine and director of the Autoimmunity Center of Excellence at the University of Colorado Health Sciences Center in Denver.

He earned his medical degree from Stanford and undergraduate degree in mathematics from the University of Southern California.

Dr. Kotzin has won numerous honors, including elected "Master" of the American College of Rheumatology, the Kirkland Scholar Award for Lupus Research, the Henry Claman Chair in Clinical Immunology, the Gretchen Kramer Award for Outstanding Contributions to Medicine, and Chairmanship of the National Institutes of Health Autoimmunity Centers of Excellence.